AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04255888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laterally positioned flap in thick periodontal phenotype.
Description: Laterally positioned flap will be performed in isolated gingival recession belonging thick periodontal phenotype .
Study NCT04255888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laterally positioned flap in thin periodontal phenotype.
Description: Laterally positioned flap will be performed in isolated gingival recession belonging thin periodontal phenotype .
Study NCT04215406 — intervention group
Intervention type: OTHER
Intervention: The level of air pollution
Description: The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.
Study NCT00813904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rThrombin, 1000 IU/mL
Description: At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
Study NCT01189513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 900105
Description: 10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
Study NCT01231568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen A
Description: Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
Study NCT01231568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen B
Description: Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
Study NCT02780167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD for 12 weeks
Study NCT01231568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen C
Description: Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
Study NCT03400059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chordate System S211 in treatment mode
Description: Chordate System S211 in treatment mode
Study NCT03400059 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Chordate System S211 in placebo mode
Description: Chordate System S211 in placebo mode
Study NCT05500573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sperm Sorting
Description: Selection of gender specific spermatozoa using a multilayer density gradient solution
Study NCT04272476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture and moxibustion
Study NCT04272476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Study NCT01231568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen D
Description: Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
Study NCT01844531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: single tablet empagliflozin
Study NCT01844531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin (Glucophage®)
Description: single tablet metformin
Study NCT01844531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin and metformin
Description: FDC tablet empagliflozin and metformin
Study NCT05604079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolarynx
Description: The device transmits electronic sound source vibrations through soft tissue, either the neck at the level of the glottis, or less commonly the check. Speech is created through movements of articulators including the lips, tongue and jaw.
Study NCT04686942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: After sonazoid
Description: 0.015ml/mg sonazoid enhanced US to detection of liver metastases.
Study NCT01596946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact tracing mode test at clinic
Study NCT01596946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-sampling at home - Sent Test Kit
Study NCT03703518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed reality
Description: This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes.
Study NCT03703518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise group
Description: This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
Study NCT02083029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulated dive reflex
Description: All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
Study NCT04186546 — intervention group
Intervention type: DEVICE
Intervention: Zephyr Valve Procedure
Description: The Pulmonx Zephyr Endobronchial Valve is an implantable bronchial valve intended to decrease volume in targeted regions of the lung. It is indicated for the treatment of patients with severe emphysema. The Zephyr Valves are placed in the diseased region of the lung using bronchoscopy. As the diseased region of the lung shrinks in size, healthier regions may expand and function more efficiently, resulting in improved breathing.
Study NCT02864238 — intervention group
Intervention type: OTHER
Intervention: electronic milestone pathway
Description: an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
Study NCT01023490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 34,5000 IU vitamin D per week
Study NCT01023490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04243304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 11C-UCB-J PET-CT
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Study NCT04243304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11C-UCB-J PET-CT
Description: Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Study NCT04243304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 18F-PE2I PET-MR
Description: Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
Study NCT04243304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-PE2I PET-MR
Description: Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
Study NCT02462369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Study NCT02462369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Study NCT03547479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VDOT
Description: In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
Study NCT03547479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VDOT + mobile money
Description: The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
Study NCT02506257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04% PHMB
Description: 0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Study NCT02506257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06% PHMB
Description: 0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Study NCT02506257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.08% PHMB
Description: 0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Study NCT02506257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PHMB Vehicle
Description: PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Study NCT03663842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Description: All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
Study NCT03760419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan.
Study NCT01924767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 Placebo
Description: po taken fasting with 240 mL water
Study NCT01924767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: po taken fasting with 240 mL water
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m² over 120 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400mg/m² over 120 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180mg/m² over 90 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5mg/kg over 90 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg over 90 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 500mg/m² over 90 mn every 2 weeks up to progression or toxicity
Study NCT01442935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m² over 90 mn every 2 weeks up to progression or toxicity
Study NCT03522558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Medical Nutrition Therapy
Description: Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
Study NCT03522558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
Study NCT01563354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: 60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
Study NCT01563354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg tables administered orally once a day
Study NCT01563354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR and Everolimus Combination
Description: Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
Study NCT01035658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
Study NCT01035658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
Study NCT03204396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
Study NCT03204396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
Description: Application of 0.5 ml normal saline (0.9% sodium chloride \[0.9% NaCl\]) once weekly for 12 weeks
Study NCT01689272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Transplantation from alive relative donor
Description: Donor kidney sampling, preservation, transport and transplantation
Study NCT04864925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colgate Total Clean Mint
Description: 2 minutes of whole mouth toothbrushing
Study NCT04864925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tom's Botanically Bright Peppermint
Description: 2 minutes of whole mouth toothbrushing
Study NCT01082809 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Sunitinib
Description: Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
Study NCT03951649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Occipital Nerve Block
Description: This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
Study NCT03951649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Occipital Nerve Block
Description: This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
Study NCT04116515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Xbox / active video games
Description: The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
Study NCT02621879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Gluteal Advancement Flap
Description: Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
Study NCT02000713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
Study NCT02000713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
Study NCT02000713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Exam
Description: Brief neurological exam will be performed.
Study NCT03396250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Description: Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
Study NCT03396250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
Study NCT04116515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated cartoon narratives
Description: The investigators would expect the animated cartoon narratives to motivate children to play more active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
Study NCT04116515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard clinical care
Description: Each clinic will provide standard clinical care to the participants.
Study NCT04116515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical care
Description: Each clinic will provide standard clinical care to the participants.
Study NCT01282346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLX Gold Shunt
Description: Single use implant
Study NCT03165071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-132577
Description: Capsule
Study NCT02272959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention bias modification treatment (ABMT)
Description: Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
Study NCT02272959 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition
Description: Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
Study NCT03387319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Racialized Stressful Event Recall
Description: Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses.
Study NCT03387319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Racialized Stressful Event Recall
Description: Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses.
Study NCT04514055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: De-epithelialized connective tissue graft wall
Description: A de-epithelialized free gingival connective tissue graft will be used to treat Cairo's recession type 2 and type 3 associated with inta-bony defects
Study NCT03093272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: a GnRH agonist
Study NCT03093272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a corticosteroid